Company: QTIWW
Filing Date: 2025-12-31
Form Type: 424B3
Source: 0001628280-25-059235
Chunk: 11

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-12-31
Form: 424B3
Chunk 11
---
 Scanner (which was later renamed “

#### QT Breast Scanner
”), received FDA’s 510(k) market clearance in June 2017.

#### NXC
The Company’s primary sales and marketing efforts in the short-to-medium term will be to focus on the $3 billion breast imaging market in United States supported by the exclusive partnership with the Company’s distribution partner, NXC Imaging, Inc. (“

#### NXC
”), a wholly owned subsidiary of Canon Medical USA, Inc. (“

#### CMSU
”). On May 31, 2023, we entered into a Sales Agent Agreement (the “

#### NXC Sales Agent Agreement
”) with NXC pursuant to which we appointed NXC as the non-exclusive agent for the sale of QT Imaging products and services in non-exclusive territories: the U.S., U.S. territories, and U.S. Department of Defense installations. Additionally, NXC was appointed as the exclusive servicer of QT Imaging products sold by NXC under the terms of the NXC Sales Agent Agreement. Effective June 10, 2024, the NXC Sales Agent Agreement was superseded by the a Distribution Agreement (the “

#### NXC Distribution Agreement
”) that was entered into with NXC on June 18, 2024. Under the NXC Distribution Agreement, NXC is appointed as the exclusive reseller to market, advertise, and resell QT Breast Scanners in the U.S. and U.S. territories.

On December 11, 2024, the Company and NXC entered into an Amended and Restated Distribution Agreement (the “

#### Amended Distribution Agreement
”), which amends and restates the NXC Distribution Agreement in its entirety, making some modifications to the NXC Distribution Agreement but retaining other terms. Among other changes made by the Amended Distribution Agreement, this amended and restated agreement provides that, unless earlier terminated or extended by mutual written agreement, has a term through December 31, 2026, and further provides that no later than five days prior to the end of each calendar quarter, NXC shall provide to the Company a forecast of the anticipated purchases of QT Breast Scanners during the subsequent twelve-month period. The Amended Distribution Agreement further provides that the forecast for 2025 and 2026 shall be no less than the Minimum Order Quantities (the “

#### MOQs
”) set forth in an exhibit to the Amended Distribution Agreement, by quarter and by year. Furthermore, all purchase orders from NXC